To examine the pharmacodynamic activity of Toc-HDO in DRG, ascending doses of Toc-HDO or ASO targeting Malat1 RNA or Scarb1 mRNA were injected i.v. into mice. This evidence concerns the gene MALAT1 and palmoplantar keratoderma-esophageal carcinoma syndrome.